Analyst Price Targets — ALXO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 5, 2026 11:47 am | — | Piper Sandler | $4.00 | $2.01 | TheFly | ALX Oncology price target raised to $4 from $3 at Piper Sandler |
| March 7, 2025 2:18 pm | — | Stifel Nicolaus | $1.50 | $1.06 | TheFly | ALX Oncology price target lowered to $1.50 from $3 at Stifel |
| June 10, 2024 8:47 am | Colin Bristow | UBS | $25.00 | $8.83 | StreetInsider | UBS Reiterates Buy Rating on ALX Oncology (ALXO) |
| June 3, 2024 8:43 am | Christopher Raymond | Raymond James | $21.00 | $9.10 | StreetInsider | Piper Sandler Reiterates Overweight Rating on ALX Oncology (ALXO) |
| April 10, 2024 12:29 pm | Bradley Canino | Stifel Nicolaus | $14.00 | $11.85 | StreetInsider | Stifel on ALX Oncology (ALXO): 'our Hold thesis is based on the lack of development strategy clarity in these opportunities' |
| August 9, 2022 10:00 am | — | Credit Suisse | $38.00 | $11.77 | Benzinga | Credit Suisse Maintains Outperform on ALX Oncology Holdings, Lowers Price Target to $38 |
| June 13, 2022 7:55 am | Bradley Canino | Stifel Nicolaus | $16.00 | $6.79 | Pulse 2.0 | ALX Oncology (ALXO) Stock Price: $16 Target And Buy Rating |
Latest News for ALXO
SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, announced that the Compensation Committee of the Board of Directors of ALX Oncology approved the granting of an inducement stock option to purchase a total of…
- Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution
ALX Oncology Holdings Inc. (NASDAQ: ALXO - Get Free Report) saw a significant growth in short interest in the month of March. As of March 31st, there was short interest totaling 2,222,798 shares, a growth of 81.7% from the March 15th total of 1,223,050 shares. Currently, 2.1% of the shares of the company are sold short.
ALX Oncology (NASDAQ: ALXO) outlined progress across its two core programs-CD47 blocker evorpacept and EGFR-targeted antibody-drug conjugate ALX2004-while providing updated clinical timelines and financial runway during its fourth-quarter and full-year 2025 results call. Leadership update and execution focus Chief Executive Officer Jason Lettmann said the company's priority remains execution and positioned 2025 as a…
ALX Oncology Holdings Inc. (ALXO) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ALXO.
U.S. House Trading
No House trades found for ALXO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.